Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa
Conditions: SARS-CoV; SARS-CoV-2 Interventions: Biological: VXCO-100; Biological: COVID-19 mRNA vaccine and VXCO-100; Biological: COVID-19 mRNA vaccine Sponsor: Vaccine Company, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: African Health | Covid Vaccine | Research | SARS | South Africa Health | Study | Vaccines